Cytosorbents Corp. | Mutual Funds

Mutual Funds that own Cytosorbents Corp.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
807,033
2.57%
38,700
0%
07/31/2018
iShares Russell 2000 ETF
594,165
1.89%
-318
0.02%
09/06/2018
Vanguard Extended Market Index Fund
321,171
1.02%
5,800
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
277,976
0.88%
0
0.04%
09/06/2018
Perinvest (Lux) SICAV - Harbour US Equity
225,000
0.72%
225,000
4.05%
06/30/2017
PowerShares DWA Small Cap Momentum Portfolio
149,490
0.48%
0
0.48%
09/05/2018
Fidelity Spartan Extended Market Index Fund
118,410
0.38%
18,532
0.01%
07/31/2018
iShares Micro Cap ETF
75,563
0.24%
0
0.1%
09/06/2018
Schwab Small Cap Index Fund
52,800
0.17%
52,800
0.02%
06/30/2018
51,951
0.17%
1,693
0.04%
07/31/2018

About Cytosorbents

View Profile
Address
7 Deer Park Drive
Monmouth Junction New Jersey 08852
United States
Employees -
Website http://cytosorbents.com
Updated 07/08/2019
CytoSorbents Corp. engages in the development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product, CytoSorb, is a extracorporeal cytokine filter and seeks to reduce cytokine storm that could otherwise cause massive inflammation, organ failure, and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.